{"id":"W1982234365","doi":"10.1007/s10549-013-2814-5","title":"Everolimus plus exemestane as first-line therapy in HR+, HER2− advanced breast cancer in BOLERO-2","year":2013,"lang":"en","type":"article","venue":"Breast Cancer Research and Treatment","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Calgary","funders":"National Cancer Institute","keywords":"Exemestane; Everolimus; Medicine; Hazard ratio; Breast cancer; Aromatase inhibitor; Internal medicine; Oncology; Clinical endpoint; Cancer; Discontinuation; Randomized controlled trial; Aromatase; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192525,0.0003757625,0.001323645,0.0002905678,0.0001676203,0.0006277128,0.0003100788,0.0002534658,0.001533859],"category_scores_gemma":[0.000997866,0.0002325535,0.001070158,0.0002759263,0.0003281522,0.0003137531,0.0005860729,0.0007763329,0.0002015292],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008655067,"about_ca_system_score_gemma":0.0006829698,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007131698,"about_ca_topic_score_gemma":0.00276343,"domain_scores_codex":[0.9996896,0.0001750637,0.00001860813,0.00004840336,0.00002463071,0.00004374672],"domain_scores_gemma":[0.999606,0.0001107736,0.0001163859,0.00002448303,0.00001325687,0.0001291475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8073487,0.01209843,0.06421459,0.001452605,0.003254072,0.000325253,0.000270716,0.002244489,0.01886566,0.000226196,0.0008021497,0.08889718],"study_design_scores_gemma":[0.3277617,0.3291293,0.3205566,0.0003729507,0.004939843,0.0008853665,0.0002988194,0.002101968,0.003785225,0.0004105648,0.009677191,0.00008049297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9944359,0.004307806,0.00006682511,0.00009897759,0.00002019662,0.0001763,0.0002452346,0.000004273058,0.0006445081],"genre_scores_gemma":[0.9926832,0.004242498,0.0004477269,0.0002914715,0.00006033642,0.0002881593,0.001027217,0.000005473118,0.0009539414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001533859,"threshold_uncertainty_score":0.006306767,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04306472712332436,"score_gpt":0.3792331120347472,"score_spread":0.3361683849114229,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}